Correspondence:
[*]
Correspondence to: Dr. Patrick L. McGeer, Aurin Biotech Inc., 4727 West Second Ave., Vancouver, BC V6T 1C1, Canada. Tel.: +1 604 822 7377; Fax: +1 604 822 7086; E-mail: mcgeerpl@mail.ubc.ca.
Abstract: We have developed a non-invasive method of diagnosing Alzheimer’s disease (AD), which can also predict the risk of its future onset. It is based on measuring salivary levels of amyloid-β protein terminating at position 42 (Aβ42). Brain deposits of this peptide are characteristic of AD. Biomarker studies indicate that such brain deposits commence a decade or more prior to clinical onset of the disease. We report here that Aβ42 is produced in all peripheral organs tested, thus establishing the generality of its production. We used this information to develop simple and sensitive tests to determine salivary Aβ42 levels. The levels were first stabilized by adding thioflavin S as an anti-aggregation agent and sodium azide as an anti-bacterial agent. We then quantitated the Aβ42 in a series of samples with ELISA type tests. Control cases showed almost identical levels of salivary Aβ42 regardless of sex or age. All AD cases secreted levels of Aβ42 more than double those of controls. Individuals at elevated risk of developing AD secreted levels comparable to the AD cases. The results establish that salivary Aβ42 levels can be used to diagnose AD as well as to predict the risk of its future onset.
Keywords: Alzheimer’s disease, amyloid-β protein, amyloid-β protein precursor, ELISA type assays, saliva, thioflavin S
